Loading...

GANX GAIN THERAPEUTICS INC Expansion Plans 8-K Filing

GN T

GNX

GAIN THERAPEUTICS INC

(GANX)

2025 8-K

Summary

Summary

KOL Event Notification

Director Resignation

Positive Study Results

Equity Offerings

Market Expansion

Increase in authorized shares

Financial Statements

Financial Results

Operational Update

Nasdaq Compliance

Management Changes

Clinical Trial Approval

Nasdaq Compliance

Preclinical Data Release

Financial Results and Busin...

Announcement of Phase 1 stu...

Annual Meeting of Stockholders

Underwriting Agreement

Earnings Reports

CFO Appointment

Financial Results Announcement

Management Changes

Underwriting Agreement and ...

Termination of Agreement

Financial Results

Earnings Reports

Annual Meeting of Stockholders

Earnings Reports

Departure of CFO

Earnings Reports

External Links:

On October 6, 2025, Gain Therapeutics, Inc. reported positive preliminary data from a Phase 1b study of GT-02287 for Parkinson's disease, showing safety and potential improvement in symptoms after 90 days of treatment. The study's continuation has been recommended based on these findings and approval has been given for an extension to 12 months.

AI Assistant

GAIN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.